Physician profile
Kyle Rickstad
NPI 1538564174
$3,128.71
in general payments reported to CMS, 2019-2025
23 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 92% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.11 · 2023: $594 · 2024: $1,224 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.79 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $371.47 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $260.22 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.06 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $166.93 | 2023-2025 | Gattex, Eohilia, Entyvio |
| Phathom Pharmaceuticals, INC. | $160.94 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $150.59 | 2023-2024 | Linzess |
| Axonics, INC. | $134.08 | 2023-2024 | Axonics |
| Vivus LLC | $122.87 | 2023-2025 | Pancreaze, Qsymia |
| Regeneron Healthcare Solutions, INC. | $99.03 | 2023-2025 | Dupixent |
| Exact Sciences Corporation | $65.65 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $33.21 | 2023-2024 | Zinplava, Dificid |
| Novo Nordisk INC | $31.13 | 2025 | |
| Alnylam Pharmaceuticals INC. | $29.38 | 2025 | Givlaari |
| Indivior INC. | $27.59 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $22.37 | 2024 | Zeposia |
| Pfizer INC. | $20.54 | 2025 | |
| Celltrion USA INC. | $20.51 | 2025 | Vegzelma |
| Kowa Pharmaceuticals America, INC. | $16.52 | 2022 | |
| Braintree Laboratories, INC. | $15.97 | 2023 | Suflave, Sutab |
| Laborie Medical Technologies Corp. | $15.87 | 2024 | Urgent Pc Neuromodulation System |
| Boston Scientific Corporation | $14.91 | 2025 | Axonics |
| Pharming Healthcare, INC. | $13.08 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Rickstad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.